Weitz, Jeffrey I. http://orcid.org/0000-0002-1092-7550
Tankó, László B.
Floege, Jürgen
Fox, Keith A. A. http://orcid.org/0000-0002-0140-2752
Bhatt, Deepak L. http://orcid.org/0000-0002-1278-6245
Thadhani, Ravi
Hung, James
Pap, Ákos F. http://orcid.org/0000-0002-2161-3151
Kubitza, Dagmar
Winkelmayer, Wolfgang C.
,
Funding for this research was provided by:
Bayer AG
Article History
Received: 12 July 2023
Accepted: 22 December 2023
First Online: 16 February 2024
Competing interests
: L.B.T., J.H., Á.F.P. and D.K. are employees of Bayer; J.I.W. holds the Canada Research Chair (Tier I) in Thrombosis and the Heart and Stroke Foundation J.F. Mustard Chair in Cardiovascular Research at McMaster University, and has served as a consultant and received honoraria from Alnylam, Alexion, Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Merck, PhaseBio, Regeneron, Servier and VarmX; J.F. reports consultancy or speaker honoraria from Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Calliditas, Chinook, Novartis, Omeros, Travere, VeraTx and Vifor; he also serves on data safety monitoring boards of trials by Novo Nordisk and Visterra. J.F. is an associate editor of <i>Kidney International</i>; K.A.A.F. reports grant funding from Bayer and AstraZeneca and consulting for Bayer, Medscape, Baim Institute for Clinical Research and the Thrombosis Research Institute; D.L.B. reports the following relationships: Advisory Boards of Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia (now a subsidiary of Bristol Myers Squibb), NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences and Stasys; Board of Directors of Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care and TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the National Institutes of Health (NIH)-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, <i>Clinical Trials and News</i>, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, <i>Harvard Heart Letter</i>), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, <i>Journal of Invasive Cardiology</i>), <i>Journal of the American College of Cardiology</i> (Guest Editor; Associate Editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and US national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, <i>Cardiology Today’s Intervention</i>), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: <i>Clinical Cardiology</i> (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women’s Hospital who assigned to Lexicon; neither I nor Brigham and Women’s Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia (now a subsidiary of Bristol Myers Squibb), NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene and 89Bio; Royalties: Elsevier (Editor, <i>Braunwald’s Heart Disease</i>); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda; R.T. has received royalties from Thermo Fisher Scientific, and consulting fees from the US Food and Drug Administration and Fresenius Medical Care; he has served in a data safety committee for Alnylam, and scientific advisory committees for Aggamin, Bayer, Comanche Biopharma and Hero; and he is on the board of directors for CAMP4, and is an equity holder with Aggamin, CAMP4, Comanche Biopharma and Hero; W.C.W. holds the Gordon A. Cain Chair in Nephrology at Baylor College of Medicine, and has served as a consultant and has received honoraria from Akebia/Otsuka, Ardelyx, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, GlaxoSmithKline, Merck Sharp & Dohme/Merck, Pharmacosmos, Reata, Unicycive and Zydus.